0001209191-21-054331.txt : 20210901 0001209191-21-054331.hdr.sgml : 20210901 20210901202127 ACCESSION NUMBER: 0001209191-21-054331 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210830 FILED AS OF DATE: 20210901 DATE AS OF CHANGE: 20210901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEONARD JOHN M CENTRAL INDEX KEY: 0001563584 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 211231491 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS INC STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: LEONARD JOHN M. DATE OF NAME CHANGE: 20121204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-30 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001563584 LEONARD JOHN M C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2021-08-30 4 M 0 11637 13.40 A 730942 D Common Stock 2021-08-30 4 M 0 27167 14.58 A 758109 D Common Stock 2021-08-30 4 S 0 2055 152.81 D 756054 D Common Stock 2021-08-30 4 S 0 2334 153.66 D 753720 D Common Stock 2021-08-30 4 S 0 7428 154.98 D 746292 D Common Stock 2021-08-30 4 S 0 15567 155.70 D 730725 D Common Stock 2021-08-30 4 S 0 4758 156.96 D 725967 D Common Stock 2021-08-30 4 S 0 3123 157.75 D 722844 D Common Stock 2021-08-30 4 S 0 2598 159.18 D 720246 D Common Stock 2021-08-30 4 S 0 725 159.98 D 719521 D Common Stock 2021-08-30 4 S 0 216 160.69 D 719305 D Common Stock 2021-08-31 4 M 0 37833 14.58 A 757138 D Common Stock 2021-08-31 4 S 0 37833 155.00 D 719305 D Common Stock 2021-09-01 4 M 0 28750 23.46 A 748055 D Common Stock 2021-09-01 4 M 0 15985 18.30 A 764040 D Common Stock 2021-09-01 4 S 0 44735 170.00 D 719305 D Common Stock 58415 I By Trust Stock Option (right to buy) 13.40 2021-08-30 4 M 0 11637 0.00 D 2030-03-01 Common Stock 11637 212501 D Stock Option (right to buy) 14.58 2021-08-30 4 M 0 27167 0.00 D 2028-12-17 Common Stock 27167 127833 D Stock Option (right to buy) 14.58 2021-08-31 4 M 0 37833 0.00 D 2028-12-17 Common Stock 37833 90000 D Stock Option (right to buy) 23.46 2021-09-01 4 M 0 28750 0.00 D 2028-03-20 Common Stock 28750 0 D Stock Option (right to buy) 18.30 2021-09-01 4 M 0 15985 0.00 D 2027-12-11 Common Stock 15985 11515 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $153.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.22 to $154.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.31 to $155.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $156.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.395 to $158.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.49 to $159.465, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.62 to $160.745, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Shares held by the John M. Leonard 2015 Irrevocable Trust. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 30, 2021. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 31, 2020. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,458 shares as of September 1, 2021. /s/James Basta Attorney-In-Fact 2021-09-01